(Provides response from Johnson & Johnson, recasts headline and first paragraph so as to add Well being Canada evaluate)
Dec 1 (Reuters) – Johnson & Johnson stated late Tuesday that well being regulators in Europe and Canada had began a real-time evaluate of its COVID-19 vaccine candidate after preliminary outcomes confirmed that the shot triggered the manufacturing of antibodies and immune cells in opposition to the virus.
The European Medicines Company stated the evaluate would go on till sufficient proof was obtainable for a proper advertising and marketing authorisation utility for the vaccine, which is being developed by the U.S. firm’s Janssen unit.
“Janssen will proceed to work with Well being Canada to finish the rolling evaluate course of and to facilitate an approval when acceptable,” J&J stated.
Rivals Moderna Inc and Pfizer–BioNTech additionally utilized for emergency authorization on Tuesday to launch their vaccine candidates in Europe.
Canada’s Well being Minister Patty Hajdu stated in a tweet earlier within the day that J&J has submitted its vaccine candidate for a evaluate by Well being Canada, making it the fourth vaccine to start the approval course of within the nation. (https://bit.ly/36r8fi9)
Canada had in August signed a cope with J&J for as much as 38 million doses of its vaccine candidate. Rival vaccine candidates by Pfizer–BioNTech, Moderna and AstraZeneca are already underneath evaluate by Well being Canada.
(Reporting by Muvija M, Manojna Maddipatla and Bhargav Acharya in Bengaluru; Modifying by Saumyadeb Chakrabarty, Arun Koyyur and Sherry Jacob-Phillips)
Our Requirements: The Thomson Reuters Belief Rules.
